• 1
    Schulte PA. Molecular Epidemiology: Principles and Practices. San Diego: Academic Press; 1993.
  • 2
    Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295300.
  • 3
    Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355: 218993.
  • 4
    Silins I, Wang X, Tadesse A, et al. A population-based study of cervical carcinoma and HPV infection in Latvia. Gynecol Oncol 2004; 93: 484492.
  • 5
    Wild CP, Jiang YZ, Sabbioni G, et al. Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. Cancer Res 1990; 50: 245251.
  • 6
    Bennett RA, Essigmann JM, Wogan GN. Excretion of an aflatoxin-guanine adduct in the urine of aflatoxin B1-treated rats. Cancer Res 1981; 41: 650654.
  • 7
    Olivier M, Hussain SP, Caron de Fromentel C, et al. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 2004: 247270.
  • 8
    Hagmar L, Stromberg U, Bonassi S, et al. Impact of types of lymphocyte chromosomal aberrations on human cancer risk: results from Nordic and Italian cohorts. Cancer Res 2004; 64: 22582263.
  • 9
    Hagmar L, Stromberg U, Tinnerberg H, Mikoczy Z. Epidemiological evaluation of cytogenetic biomarkers as potential surrogate end-points for cancer. IARC Sci Publ 2004: 207215.
  • 10
    Chen J, Stampfer MJ, Hough HL, et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 1998; 58: 33073311.
  • 11
    Norppa H. Cytogenetic biomarkers and genetic polymorphisms. Toxicol Lett 2004; 149: 309334.
  • 12
    Potter JD, Cerhan, Jr, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 1995; 4: 319326.
  • 13
    Colditz GA, Rosner BA, Chen WY, et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004; 96: 218228.
  • 14
    Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529537.
  • 15
    Cubie A. When is an STD not an STD? HPV and cervical cancer. Microbiol Today 2003; 30: 5860.
  • 16
    Reichman RC. Human Papillomaviruses. In: BraunwaldE, FauciAS, KasperDL, et al. (eds.) Harrison's Principles of Internal Medicine, 15th ed. New York: McGraw-Hill; 2001: 11181120.
  • 17
    Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer – burden and assessment of causality. J Natl Cancer Inst Monographs 2003; 31: 313.
  • 18
    Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 1219.
  • 19
    Schiffman MH, Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 2003; 95: E2E2.
  • 20
    Davey DD, Zarbo RJ. Human papillomavirus testing-are you ready for a new era in cervical cancer screening? Arch Pathol Lab Med 2003; 127: 927929.
  • 21
    Hubbard RA. Human papillomavirus testing methods. Arch Pathol Lab Med 2003; 127: 940945.
  • 22
    Schiffman MH, Schatzkin A. Test reliability is critically important to molecular epidemiology: an example from studies of human papillomavirus infection and cervical neoplasia. Cancer Res 1994; 54: 1944s1947s.
  • 23
    Bosch FX, de Sanjose S, Munoz N. Correspondence Re: M. Schiffman and A. Schatzkin, Test reliability is critically important to molecular epidemiology: an example from studies of human papillomavirus infection and cervical neoplasia. Cancer Res 1994;54:1944s–1947s. Cancer Res 1994; 54: 62886289.
  • 24
    Guerrero E, Daniel RW, Bosch FX, et al. Comparison of ViraPap, Southern hybridization, and polymerase chain reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer. J Clin Microbiol 1992; 30: 29512959.
  • 25
    Song S, Liem A, Miller JA, Lambert PF. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology 2000; 267: 141150.
  • 26
    Harris TG, Kulasingam SL, Kiviat NB, et al. Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. Am J Epidemiol 2004; 159: 834842.
  • 27
    Daya-Grosjean L, Dumaz N, Sarasin A. The specificity of p53 mutation spectra in sunlight induced human cancers. J Photochem Photobiol B 1995; 28: 115124.
  • 28
    Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88: 1012410128.
  • 29
    Nakazawa H, English D, Randell PL, et al. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci USA 1994; 91: 360364.
  • 30
    Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773776.
  • 31
    Jonason AS, Kunala S, Price GJ, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996; 93: 1402514029.
  • 32
    Dumaz N, van Kranen HJ, de Vries A, et al. The role of UV-B light in skin carcinogenesis through the analysis of p53 mutations in squamous cell carcinomas of hairless mice. Carcinogenesis 1997; 18: 897904.
  • 33
    Kress S, Sutter C, Strickland PT, et al. Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. Cancer Res 1992; 52: 64006403.
  • 34
    Ichihashi M, Ueda M, Budiyanto A, et al. UV-induced skin damage. Toxicology 2003; 189: 2139.
  • 35
    Etzel RA. Mycotoxins. JAMA 2002; 287: 425427.
  • 36
    International Agency for Research on Cancer. Aflatoxins. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans 2002; 82: 171300.
  • 37
    Kerr RA. Indoor radon: the deadliest pollutant. Science 1988; 240: 606608.
  • 38
    Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429431.
  • 39
    Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427428.
  • 40
    Staib F, Hussain SP, Hofseth LJ, et al. TP53 and liver carcinogenesis. Hum Mutat 2003; 21: 201216.
  • 41
    Bennett IC, Gattas M, Teh BT. The management of familial breast cancer. Breast 2000; 9: 247263.
  • 42
    Samowitz WS, Curtin K, Lin HH, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 2001; 121: 830838.
  • 43
    Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338: 14811487.
  • 44
    Leach FS, Nicolaides NC, Papadopolos N, et al. Mutations of a mutS homology in hereditary nonpolyposis colorectal cancer. Cell 1993; 75: 12151225.
  • 45
    Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homology MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 10271038.
  • 46
    Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371: 7580.
  • 47
    Plaschke J, Kruger S, Dietmaier W, et al. Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue. Hum Mutat 2004; 23: 285285.
    Direct Link:
  • 48
    Kize MG, Salmon CP, Pais P, Felton JS. Food heating and the formation of heterocyclic aromatic amine and polycyclic aromatic hydrocarbon mutagens/carcinogens. Adv Exp Med Biol 1999; 459: 179193.
  • 49
    Felton JS, Knize MG, Salmon CP, et al. Human exposure to heterocyclic amine food mutagens/carcinogens: relevance to breast cancer. Environ Mol Mutagen 2002; 39: 112118.
  • 50
    Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003; 348: 17771785.
  • 51
    Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 18281837.
  • 52
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 21292139.